House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The AHA Sept. 4 expressed support for the Hospitals As Naloxone Distribution Sites Act (H.R. 5120), legislation that would require Medicare and Medicaid to…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The AHA’s Society for Health Care Strategy & Market Development Aug. 21 announced Donna Teach, chief marketing and communications officer for Nationwide…
Perspective
The job description for the ideal health care leader in coming years might read something like this:Wanted: Bold, compassionate innovator who unites clinical…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…